WHO classifies new Covid strain JN.1 as ‘variant of interest’
The World Health Organization (WHO) on Tuesday classified the JN.1 coronavirus strain as a "variant of interest" and said current evidence shows risk to public health was low from the strain.
At least two experts told Reuters that while the strain can evade the immune system and transmit more easily than other currently circulating variants, it has not shown any signs of more severe disease.
JN.1 was previously classified a variant of interest as part of its parent lineage BA.2.86, but WHO has now classified it as a separate variant of interest.
WHO said current vaccines will continue to protect against severe disease and death from JN.1 and other circulating variants of the COVID-19 virus.
The U.S. Centers for Disease Control and Prevention (CDC) said earlier this month the subvariant JN.1 makes up about an estimated 15% to 29% of cases in the United States as of Dec. 8, according to the agency's latest projections.
The CDC had said currently there was no evidence that JN.1 presents an increased risk to public health relative to other currently circulating variants and an updated shot could keep Americans protected against the variant.
JN.1 was first detected in the United States in September, according to the CDC.
Last week, China detected seven infections of the COVID subvariant.
For more news & updates, check out the link given below:
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.